{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010615","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.323299+00:00","generated_at":"2026-06-17T11:16:53.049415+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AN2 Therapeutics reports Q4 2022 net loss $11.8M, full year loss $41.0M; cash $99.3M","bullets":["Net loss for Q4 2022 was $11.8M and full year 2022 was $41.0M.","R&D expenses for full year 2022 were $29.5M vs $16.9M in 2021; G&A $12.8M vs $4.7M.","Cash, cash equivalents and investments totaled $99.3M at Dec 31, 2022, expected to fund through mid-2024.","Phase 2/3 pivotal trial for epetraborole in MAC lung disease approaching 60 sites; Phase 2 enrollment expected to complete mid-2023.","Awarded up to $17.8M NIAID contract to develop epetraborole for melioidosis using non-dilutive funding."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010615","json":"https://secwatch.observer/filing/0000950170-23-010615.json","markdown":"https://secwatch.observer/filing/0000950170-23-010615.md","text":"https://secwatch.observer/filing/0000950170-23-010615.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023010615/0000950170-23-010615-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023010615/antx-20230329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T11:16:53.049415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d3d19fc50e5fbc54884eb7e6eb3c55e1572c9db","claim":"AN2 Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income net loss was $11.8 million and $41.0 million, respectively.","evidence_excerpt":"AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023010615/0000950170-23-010615-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Net income","value":"net loss was $11.8 million and $41.0 million, respectively"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}